Evidence map›Paper›PMID 32914354›Full record

ArticleBreast cancer research and treatment2021

Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.

Pietro Sollena, Vasiliki Nikolaou, Nikolaos Soupos, Elias Kotteas, Dimitra Voudouri, Alexandros J Stratigos, Davide Fattore, Maria Carmela Annunziata, Armando Orlandi, Lucia Di Nardo and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Ribociclib-induced Vitiligo: a Case Report.Dermatology practical & conceptual · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Pietro SollenaUOC Dermatologia, Fondazione Policlinico Universitario A. Gemelli-IRCCS, L.go Agostino Gemelli 8, 00168, Rome, Italy. pietrosollena@virgilio.it.ORCID http://orcid.org/0000-0002-1632-7791
Vasiliki NikolaouDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hopital, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos SouposSecond Department of Medical Oncology, Agii Anargiri General Oncological Hospital of Kifissia, Athens, Greece.
Elias KotteasThird Department of Medicine, Oncology Unit, Sotiria General HospitalNational and Kapodistrian University, Athens School of Medicine, Athens, Greece.
Dimitra VoudouriDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hopital, National and Kapodistrian University of Athens, Athens, Greece.
Alexandros J StratigosDermato-Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hopital, National and Kapodistrian University of Athens, Athens, Greece.
Davide FattoreSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Maria Carmela AnnunziataSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Armando OrlandiMedical Oncology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
Lucia Di NardoDermatologia,, Università Cattolica del Sacro Cuore, Rome, Italy.
Zoe ApallaSecond Dermatology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Florian DeilhesOncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Maria Concetta RomanoSan Camillo Forlanini Hospital, Rome, Italy.
Gabriella FabbrociniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Vincent SibaudOncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Ketty PerisUOC Dermatologia, Fondazione Policlinico Universitario A. Gemelli-IRCCS, L.go Agostino Gemelli 8, 00168, Rome, Italy.
European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group
National and Kapodistrian University of Athens · GRUniversity of Naples Federico II · ITAgostino Gemelli University Polyclinic · ITInstitut universitaire du cancer de Toulouse Oncopole · FRUniversità Cattolica del Sacro Cuore · ITAristotle University of Thessaloniki · GRCarlo Forlanini Hospital · ITHospital Agioi Anargyroi · GRSotiria General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntroduction of cyclin-dependent inhibitors was a milestone in therapeutics for patients with estrogen receptor+/HER2- metastatic breast cancer. Despite the wide use of such agents and remarkable improvement of survival rates, drug-related adverse events are not yet fully characterized. We describe vitiligo-like lesions as a new adverse event occurring in patients with advanced breast cancer treated with cyclin-dependent inhibitors.

methodsWe performed an international retrospective study including patients with advanced breast cancer who developed vitiligo-like lesions during treatment with cyclin-dependent kinases 4 and 6 inhibitors, in the period January 2018-December 2019. Patients > 18 years, both males and females, were recruited at six Dermatology Departments located in Italy (3), France (1) and Greece (2). We evaluated epidemiological and clinical characteristics, impact on quality of life and outcome of vitiligo-like lesions in patients treated with cyclin-dependent 4 and 6 inhibitors. The percentage of skin involved by vitiligo-like lesions was assessed using the Body Surface Area (BSA) score. Changes in patients' quality of life were investigated through the evaluation of the Dermatology Life Quality Index (DLQI) questionnaire.

resultsSixteen women (median age: 62.5 years; range 40-79 years) treated with cyclin-dependent kinases 4 and 6 inhibitors for advanced breast cancer presented with vitiligo-like lesions during follow-up visits. Cutaneous lesions consisted of white, irregular macules and patches located mainly on sun-exposed areas in 11/16 patients or diffuse to the entire body surface in 5/16. Cutaneous lesions clearly impaired the quality of life of patients tested (DLQI ≥ 10).

conclusionsWe present for the first time, to our knowledge, a case series of vitiligo-like lesions developing in patients with advanced breast cancer treated with cyclin-dependent kinases 4 and 6 inhibitors. We showed that such lesions further impair the patients' quality of life and their treatment is challenging.

Indexed as

Breast NeoplasmsVitiligoAdultAgedFemaleFranceHumansItalyMaleMiddle AgedQuality of LifeRetrospective StudiesAdvanced breast cancerCDK4/6 inhibitorsSkin adverse eventVitiligo-like lesion

Identifiers

PMID32914354
OpenAlexW3086263017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.